Determination of Levosulpiride in Human Plasma Using HPLC Method and its Application to Bioequivalence Study

Author(s):  
Ayan Das
2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Shravan Bankey ◽  
Ganesh Tapadiya ◽  
Jasvant Lamale ◽  
Deepti Jain ◽  
Shweta Saboo ◽  
...  

A simple, accurate, and precise HPLC method was developed and validated for determination of rimonabant in human plasma. Following liquid-liquid extraction, chromatographic separation was accomplished using C18 column with mobile phase consisting of acetonitrile : water (90 : 10, v/v), drug was detected at 260 nm using UVdetector. The LOD and LOQ were 3.0 and 10.0 μg/L, respectively. The method is linear in the interval 50.0–1000.0 μg/L. The average extraction recovery of drug from plasma was found to be 92.2%. The percent CV of the method was found to be less than 10.8%, and accuracy was found between 94.5 and 106.7%. The assay may be applied to a pharmacokinetic and bioequivalence study of rimonabant.


2010 ◽  
Vol 93 (3) ◽  
pp. 876-881 ◽  
Author(s):  
Ziba Islambulchilar ◽  
Hadi Valizadeh ◽  
Parvin Zakeri-Milani

Abstract A simple and rapid HPLC method with UV detection was developed for the determination of pioglitazone in human plasma. The method was based on protein precipitation using perchloric acid on an ODS column. The mobile phase consisted of a mixture of phosphate buffer, methanol, acetonitrile, and 12 M perchloric acid (54 + 33 + 12 + 1, v/v/v/v). The UV detector was set at 269 nm. Under these conditions, the retention time of pioglitazone was 5.2 min. The standard curve was linear over the range of 502000 ng/mL pioglitazone in human plasma. The within-day and between-day precision studies showed high reproducibility, with CV less than 5. The LOQ was 44.2 ng/mL. The method has been applied to a bioequivalence study after administration of pioglitazone as 30 mg tablets to 12 healthy volunteers.


2020 ◽  
Vol 20 (13) ◽  
pp. 1053-1059
Author(s):  
Mahmoud M. Sebaiy ◽  
Noha I. Ziedan

Background: Allergic diseases are considered as the major burden on public health with increased prevalence globally. Histamine H1-receptor antagonists are the foremost commonly used drugs in the treatment of allergic disorders. The target drug in this study, loratadine, belongs to this class of drugs and its biometabolite desloratadine which is also a non-sedating H1 receptor antagonist with anti-histaminic activity being 2.5 to 4 times greater than loratadine. This study aimed to develop and validate a novel isocratic Reversed-phase High-Performance Liquid Chromatography (RP-HPLC) method for rapid and simultaneous separation and determination of loratadine and its metabolite, desloratadine in human plasma. Methods: The drug extraction method from plasma was based on protein precipitation technique. The separation was carried out on a Thermo Scientific BDS Hypersil C18 column (5μm, 250 x 4.60 mm) in a mobile phase of MeOH: 0.025M KH2PO4 adjusted to pH 3.50 using orthophosphoric acid (85: 15, v/v) at an ambient temperature. The flow rate was maintained at 1 mL/min and maximum absorption was measured using the PDA detector at 248 nm. Results: The retention times of loratadine and desloratadine in plasma samples were recorded to be 4.10 and 5.08 minutes, respectively, indicating a short analysis time. Limits of detection were found to be 1.80 and 1.97 ng/mL for loratadine and desloratadine, respectively, showing a high degree of sensitivity of the method. The method was then validated according to FDA guidelines for the determination of the two analytes in human plasma. Conclusion: The results obtained indicate that the proposed method is rapid, sensitive in the nanogram range, accurate, selective, robust and reproducible compared to other reported methods.


Sign in / Sign up

Export Citation Format

Share Document